Search company, investor...
PathoVax company logo

PathoVax

pathovax.com

Founded Year

2014

Stage

Seed VC | Alive

Total Raised

$3.25M

Last Raised

$2.75M | 4 yrs ago

About PathoVax

PathoVax is a biotech company developing a cost-effective human papillomavirus (HPV) vaccine machine with universal protection. PathoVax's pilot vaccine RGVax promises to provide protection against all 15 oncogenic HPVs and many others that cause various warts.

Headquarters Location

1812 Ashland Ave Suite 100

Baltimore, Maryland, 21205,

United States

Missing: PathoVax's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PathoVax's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PathoVax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PathoVax is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

PathoVax Patents

PathoVax has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/21/2018

3/29/2022

Clusters of differentiation, Vaccines, Immunology, Immune system, Transcription factors

Grant

Application Date

6/21/2018

Grant Date

3/29/2022

Title

Related Topics

Clusters of differentiation, Vaccines, Immunology, Immune system, Transcription factors

Status

Grant

Latest PathoVax News

JHU startup PathoVax raises $2.75M, grows team - Technical.ly Baltimore

Oct 19, 2018

(Courtesy photo) PathoVax , a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said. The equity funding round was led by United Heath Investments. The life science investment group is led by Dr. Alan Zhu, who is also director of the Baltimore-based Chinese Association for Medical Professionals , which counts 800 physicians as members and seeks to strengthen ties between medical communities in the U.S. and China. Private investors also participated. The startup is developing RGVax, a vaccine that is designed to protect against all cancer-causing forms of HPV. Vaccines against the are already available, but only protect against some strains of the disease. Wang and cofounder Weijie Poh began working on the technology while they were PhD students working in the lab of inventor Richard Roden at the Johns Hopkins University School of Medicine. The cofounders are alums of 43North, a Buffalo accelerator. Late last year, the company also received U.S. Small Business Innovation Research grant funding totaling about $2.3 million, Wang said. “Since then we’ve grown from a 2-person team to six employees and have been focused on pushing the vaccine toward first in human trials,” Wang said. The startup also recently moved into Johns Hopkins’ FastForward 1812 innovation hub. Along with targeting clinical trials in the first half of 2020, the company is also identifying other applications of the technology. The equity funding, Wang said, is aimed at “building the business side of the company.” The company is looking to bring on team members who are experienced in areas such as management and manufacturing.

PathoVax Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PathoVax Rank

PathoVax Frequently Asked Questions (FAQ)

  • When was PathoVax founded?

    PathoVax was founded in 2014.

  • Where is PathoVax's headquarters?

    PathoVax's headquarters is located at 1812 Ashland Ave, Baltimore.

  • What is PathoVax's latest funding round?

    PathoVax's latest funding round is Seed VC.

  • How much did PathoVax raise?

    PathoVax raised a total of $3.25M.

  • Who are the investors of PathoVax?

    Investors of PathoVax include United Heath Investments, Harvard Venture Incubation Program, Harvard Life Lab, 43North, MassChallenge and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.